Efficacy of treatments for <i>β</i>-coronaviruses associated respiratory diseases: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

ZENG Xueyang ¹ , ZHOU Qingxin ¹ , ZHANG Jingxue ¹ , YANG Zhirong ² , CAI Xianming ³ , CAI Shan ³ , TAN Xiaoyu ³ , YANG Qingqing ¹ , WU Shanshan ⁴ , CHEN Yahong ⁵ ,  SUN Feng ¹

1. Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, P.R.China;
2. Primary Care Unit, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridgeshire CB1 8RN, UK;
3. Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, P.R.China;
4. National Clinical Research Center of Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R.China;
5. Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, P.R.China;

Corresponding?author：

SUN Feng, Email: sunfeng@bjmu.edu.cn

Keywords：

SARS-CoV-2; β-coronaviruses; Treatment; Efficacy; Systematic review; Meta-analysis

DOI：

10.7507/1672-2531.202105133

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy of treatments for β-coronaviruses.Methods PubMed, EMbase, Web of Science, The Cochrane Library, SinoMed, CNKI and WanFang Data databases were electronically searched to collect randomized controlled trials (RCTs) and non-randomized controlled trials (non-RCTs) of treatments for β-coronaviruses from inception to June 17^th, 2020. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed using Stata 14.0 software.Results A total of 109 studies invoving 23 210 patients were included. The results of the systematic review showed that compared with standard of care, corticosteroids could reduce mortality and increase cure rate for COVID-19. However, chloroquine could decrease cure rate. In severe acute respiratory syndrome (SARS) patients, corticosteroids could decrease the cure rate. In Middle East respiratory syndrome (MERS) patients, ribavirin/interferon/both drugs showed higher mortality.Conclusions The currently limited evidence shows that corticosteroids may be effective to COVID-19 patients while having limited effects on SARS patients. Hydroxychloroquine or chloroquine may have negative effects on COVID-19 patients. Ribavirin/interferon may be harmful to MERS patients. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify the above conclusions.

Citation： ZENG Xueyang, ZHOU Qingxin, ZHANG Jingxue, YANG Zhirong, CAI Xianming, CAI Shan, TAN Xiaoyu, YANG Qingqing, WU Shanshan, CHEN Yahong, SUN Feng. Efficacy of treatments for β-coronaviruses associated respiratory diseases: a systematic review. Chinese Journal of Evidence-Based Medicine, 2021, 21(9): 1055-1066. doi: 10.7507/1672-2531.202105133 Copy

1.	Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol, 2020, 92(4): 441-447.
2.	Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses - a statement of the coronavirus study group. BioRxiv, 2020: 2020-2022.
3.	World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Available at: https://www.who.int/publications/m/item/summary-of-probable-sars-cases-with-onset-of-illness-from-1-november-2002-to-31-july-2003.
4.	International Committee on Taxonomy of Viruses. ICTV master species list 2018b. v2. Available at: https://talk.ictvonline.org/files/master-species-lists/m/msl/8266.
5.	Zhu Y, Li C, Chen L, et al. A novel human coronavirus OC43 genotype detected in mainland China. Emerg Microbes Infect, 2018, 7(1): 173.
6.	World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
7.	COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. American: National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/.
8.	Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis, 2020: ciaa478.
9.	Alhazzani W, M?ller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med, 2020, 48(6): e440-e469.
10.	Rochwerg B, Agarwal A, Zeng L, et al. Remdesivir for severe covid-19: a clinical practice guideline. BMJ, 2020, 370: m2924.
11.	劉素彥, 王連嵋, 趙雍, 等. 《新型冠狀病毒肺炎診療方案》推薦的中藥注射劑治療呼吸系統感染性疾病的研究進展. 中國實驗方劑學雜志, 2020, 26(12): 1-13.
12.	Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg, 2011, 39(2): 91-92.
13.	國家衛生健康委員會, 國家中醫藥管理局. 新型冠狀病毒肺炎診療方案(試行第八版). 中國病毒病雜志, 2020, 10: 321-328.
14.	World Health Organization. Clinical management of COVID-19. Living guidance. Available at: https://www.who.int/publications/i/item/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
15.	Higgins JP, Altman DG, G?tzsche PC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 2011, 343: d5928.
16.	Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 2016, 355: i4919.
17.	Agresti A. On logit confidence intervals for the odds ratio with small samples. Biometrics, 1999, 55(2): 597-602.
18.	Anscombe FJ. On estimating binomial response relations. Biometrika, 1956, 43(3-4): 461-464.
19.	Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med, 2020, 383(19): 1813-1826.
20.	Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol, 2020, 146(1): 137-146.
21.	Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother, 2020, 64(9): e01061-1020.
22.	Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med, 2020, 383(19): 1827-1837.
23.	Horby P, Lim WS, Emberson J, et al. Effect of dexamethasone in hospitalized patients with COVID-19 - preliminary report. MedRxiv, 2020: 2020-2026.
24.	Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine, 2021, 85: 153242.
25.	Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA, 2020, 324(5): 460-470.
26.	傅曉霞, 林路平, 譚行華. 中西醫結合治療新型冠狀病毒肺炎 37 例臨床研究. 中藥新藥與臨床藥理, 2020, 31(5): 600-604.
27.	李亞冬, 張文靜. 新冠肺炎中西醫治療方案臨床效果評價. 光明中醫, 2020, 35(9): 1273-1275.
28.	余平, 李葉子, 萬少兵, 等. 連花清瘟顆粒聯合阿比多爾治療輕度新型冠狀病毒肺炎的療效觀察. 中國藥學雜志, 2020, 55(12): 1042-1045.
29.	張傳濤, 楊洋, 由鳳鳴, 等. 從“疫毒夾濕”論治新型冠狀病毒肺炎(COVID-19)的臨床研究. 中藥藥理與臨床, 2020, 36(2): 43-46.
30.	張又莉, 雷亮, 徐勇, 等. 金銀花口服液治療新型冠狀病毒肺炎80例臨床療效分析. 中國藥業, 2020, 29(9): 23-26.
31.	鄭子洲, 白志剛, 李常杰, 等. 中醫辨證治療新型冠狀病毒肺炎效果觀察. 交通醫學, 2020, 34(2): 117-118.
32.	周外民, 趙富明, 李榜龍, 等. 甘草酸二胺在普通型新型冠狀病毒肺炎患者治療中的臨床價值. 病毒學報, 2020, 36(2): 160-164.
33.	Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med, 2020, 382(19): 1787-1799.
34.	Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020, 395(10236): 1569-1578.
35.	Li Y, Xie Z, Lin W, et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Med (NY), 2020, 1(1): 105-113.
36.	Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet, 2020, 395(10238): 1695-1704.
37.	Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. MedRxiv, 2020: 2020-2023.
38.	Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ, 2020, 369: m1849.
39.	陳軍, 劉丹萍, 劉莉, 等. 硫酸羥氯喹治療 2019 冠狀病毒病(COVID-19)普通型患者的初步研究. 浙江大學學報(醫學版), 2020, 49: 215-219.
40.	Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open, 2020, 3(4): e208857.
41.	Zhong M, Sun A, Xiao T, et al. A randomized, single-blind, group sequential, active-controlled study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19). MedRxiv, 2020: 2020-2024.
42.	Zheng F, Zhou Y, Zhou Z, et al. A novel protein drug, novaferon, as the potential antiviral drug for COVID-19. MedRxiv, 2020: 2020-2024.
43.	Lou Y, Liu L, Yao H, et al. Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. Eur J Pharm Sci, 2021, 157: 105631.
44.	Zhang Z, Wang S, Tu X, et al. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19. J Med Virol, 2020, 92(11): 2631-2636.
45.	Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA, 2020, 323(24): 2493-2502.
46.	Panagopoulos P, Petrakis V, Panopoulou M, et al. Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection. J Chemother, 2021, 33(3): 193-197.
47.	Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020, 5(9): 1036-1041.
48.	Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. MedRxiv, 2020: 2020-2024.
49.	Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol, 2020, 2(6): e325-e331.
50.	Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med, 2020, 76: 43-49.
51.	Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med, 2020, 76: 31-35.
52.	Mallat J, Hamed F, Balkis M, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease. Medicine (Baltimore), 2020, 99(52): e23720.
53.	Lian N, Xie H, Lin S, et al. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect, 2020, 26(7): 917-921.
54.	Huang M, Li M, Xiao F, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. MedRxiv, 2020: 2020-2024.
55.	Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med, 2020, 382(25): 2411-2418.
56.	Yuan M, Xu X, Xia D, et al. Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis. Shock, 2020, 54(5): 638-643.
57.	程德忠, 王文菊, 李毅, 等. 51 例新型冠狀病毒肺炎患者應用中藥連花清瘟療效分析: 多中心回顧性研究. 天津中醫藥, 2020, 37: 509-516.
58.	李曠宇, 安薇, 夏飛, 等. 清肺排毒湯加減方聯合抗病毒藥物治療新型冠狀病毒肺炎的回顧性研究. 中草藥, 2020, 51: 2046-2049.
59.	李威, 柳德兵. 甲潑尼龍琥珀酸鈉治療新型冠狀病毒肺炎的有效窗口期. 武漢大學學報(醫學版), 2020, 41(6): 870-874.
60.	李新剛, 徐艷利, 王琳, 等. 糖皮質激素在新型冠狀病毒肺炎重型患者治療中的臨床研究. 首都醫科大學學報, 2020, 41(3): 345-349.
61.	柳麗麗, 馮毅, 孫東, 等. 阿比多爾聯合連花清瘟膠囊治療新型冠狀病毒肺炎的臨床觀察. 廣東醫學, 2020, 41(12): 1207-1210.
62.	秦婭藍, 宋玉燕, 周璐, 等. 熱毒寧聯合甲潑尼龍治療重癥新型冠狀病毒肺炎臨床療效評價. 中國藥業, 2020, 29(9): 19-22.
63.	時佳, 楊宗國, 葉晨, 等. 中西醫結合治上海地區 49 例非危重型新型冠狀病毒肺炎臨床療效觀察. 上海中醫藥雜志, 2020, 54(4): 30-35.
64.	魏茹楠, 蔣賢高, 馬春蓮, 等. 浙江省新型冠狀病毒肺炎患者早期阿比多爾+洛匹那韋/利托那韋+重組干擾素 α-2b 聯合抗病毒治療的多中心、前瞻性研究. 中華臨床感染病雜志, 2020, 13(1): 9-15.
65.	溫春燕, 謝志偉, 李粵平, 等. 洛匹那韋/利托那韋及阿比多爾治療新型冠狀病毒肺炎的療效和安全性觀察. 中華內科雜志, 2020, 59(8): 605-609.
66.	Xu P, Huang J, Fan Z, et al. Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study. Microbes Infect, 2020, 22(4-5): 200-205.
67.	楊倩, 孫勤國, 江波, 等. 中西醫結合治療新型冠狀病毒肺炎重癥患者的回顧性臨床研究. 中草藥, 2020, 51(8): 2050-2054.
68.	楊勇, 吳慕禹, 苗麗霞, 等. 高壓氧輔助治療新型冠狀病毒肺炎的介入時機及其臨床療效. 中國醫學物理學雜志, 2020, 37(5): 641-643.
69.	余愛榮, 范星, 趙燕, 等. 洛匹那韋/利托那韋聯合其他抗病毒藥治療新型冠狀病毒肺炎的療效與安全性. 醫藥導報, 2020, 39: 628-632.
70.	Carlucci PM, Ahuja T, Petrilli C, et al. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. MedRxiv, 2020: 2020-2025.
71.	Quartuccio L, Sonaglia A, McGonagle D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care. J Clin Virol, 2020, 129: 104444.
72.	Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust, 2020, 212(9): 416-420.
73.	Yu B, Li C, Chen P, et al. Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. MedRxiv, 2020: 2020-2024.
74.	Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Infect, 2020, 81(1): e1-e5.
75.	薛平, 柳湘潔, 雷超, 等. 老年普通型新型冠狀病毒肺炎治療中短期小劑量糖皮質激素應用觀察. 山東醫藥, 2020, 60(15): 1-5.
76.	Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for treatment of severe covid-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms, 2020, 8(5): 695.
77.	Lan X, Shao C, Zeng X, et al. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study. Int J Clin Pharmacol Ther, 2021, 59(5): 378-385.
78.	夏文廣, 安長青, 鄭嬋娟, 等. 中西醫結合治療新型冠狀病毒肺炎 34 例臨床研究. 中醫雜志, 2020, 61: 375-382.
79.	瞿香坤, 郝樹立, 馬景賀, 等. 疏風解毒膠囊聯合阿比多爾治療新型冠狀病毒肺炎的回顧性研究. 中草藥, 2020, 51(5): 1167-1170.
80.	陳軍, 凌云, 席秀紅, 等. 洛匹那韋利托那韋和阿比多爾用于治療新型冠狀病毒肺炎的有效性研究. 中華傳染病雜志, 2020, 38: 86-89.
81.	Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing), 2020, 6(10): 1192-1198.
82.	Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 2020, 56(1): 105949.
83.	劉凡. 中西醫結合治療新型冠狀病毒肺炎 42 例療效觀察. 中國管理科學研究院商學院管理創新成果匯編(一). 北京: 中國管理科學研究院商學院, 2020: 7.
84.	Fadel R, Morrison AR, Vahia A, et al. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis, 2020, 71(16): 2114-2120.
85.	肖琦, 蔣茵婕, 吳思思, 等. 中藥疏風解毒膠囊聯合阿比多爾治療輕癥新型冠狀病毒肺炎的價值分析. 中國中醫急癥, 2020, 29: 756-758.
86.	王融冰, 劉軍民, 江宇泳, 等. 中西醫結合治療 SARS 療效初步分析. 中國中西醫結合雜志, 2003, 23(7): 492-493.
87.	Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol, 2003, 52(Pt 8): 715-720.
88.	張立山, 武維屏, 侯一軍, 等. 中西醫結合治療傳染性非典型肺炎 30 例臨床觀察. 中醫雜志, 2004, 45(9): 675-677.
89.	張允嶺, 張曉梅, 金耀文, 等. 中西醫結合治療 65 例非典型肺炎(SARS)的臨床研究. 北京中醫藥大學學報, 2003, 26(6): 60-64.
90.	趙春惠, 李秀惠, 張可, 等. 77 例 SARS 患者中西醫結合治療隨機對照研究. 中國中西醫結合急救雜志, 2003, 10(4): 197-200.
91.	黃小波, 李宗信, 李斌, 等. 中西醫結合治療 SARS 的臨床療效觀察. 中國中醫藥信息雜志, 2004, 11(2): 144-145.
92.	李志軍, 李慶, 鮑鳳和, 等. 中西醫結合治療 SARS 臨床研究. 杭州: 全國 SARS 防治學術交流會, 2003.
93.	王融冰, 劉軍民, 吳云忠, 等. 中西醫結合治療 SARS 療效分析. 北京: 中醫藥防治 SARS 學術研討會, 2003.
94.	張漢豐, 馬國強, 郝富, 等. 蒙藥清熱八味散(額日赫木-8)對 SARS 的臨床研究. 內蒙古醫學雜志, 2004, 36(10): 732-734.
95.	李海, 盧誠震, 唐克誠, 等. 柴胡滴丸聯合藿香正氣滴丸治療 SARS 的臨床觀察. 中國中西醫結合雜志, 2004, 24(4): 321-324.
96.	任愛民, 張淑文, 王寶恩, 等. 中西醫結合治療 SARS 的臨床研究. 杭州: 全國 SARS 防治學術交流會, 2003.
97.	李宗信, 黃小波, 李斌, 等. 中西醫結合治療傳染性非典型肺炎 122 例臨床研究. 中醫雜志, 2004, 45(7): 510-511.
98.	Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol, 2004, 31(4): 304-309.
99.	王融冰, 劉軍民, 江宇泳, 等. 中醫藥為主治療 SARS11 例. 北京中醫, 2003, 22(3): 8-9.
100.	張紓難. 中西醫結合治療 SARS 所致肺纖維化療效總結及其臨床特點的分析. 中國全科醫學, 2003, 6(7): 576-577.
101.	黃小波, 李宗信, 李斌, 等. 中西醫結合治療老年 SARS 患者的臨床研究. 中國老年學雜志, 2004, 24(3): 223-225.
102.	Li S, Wang R, Zhang Y, et al. Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS. Am J Chin Med, 2006, 34(6): 937-947.
103.	張曉梅, 張允嶺, 楊祖福, 等. 非典 1, 2, 3 號系列方藥治療 SARS 的臨床療效觀察. 中國醫藥學報, 2003, 18(6): 323-325.
104.	夏祖昌, 張重剛, 徐立然, 等. 中西醫結合治療 SARS 證治規律的臨床研究. 中華中醫藥雜志, 2005, 20(4): 243-244.
105.	康靜, 陳恒雯, 劉仲云. 中西醫結合治療傳染性非典型肺炎 43 例臨床觀察. 山西中醫, 2003, 19(4): 34-35.
106.	Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect, 2004, 10(7): 676-678.
107.	Muller MP, Dresser L, Raboud J, et al. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy, 2007, 27(4): 494-503.
108.	李平, 劉保延, 翁維良, 等. 中西醫結合治療對 SARS 肺部炎癥的影響研究. 北京中醫藥大學學報, 2005, 28(4): 55-57.
109.	Leong HN, Ang B, Earnest A, et al. Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003. Trop Med Int Health, 2004, 9(8): 923-927.
110.	付琦, 李志剛, 賈寶輝, 等. 中西藥聯合治療 SARS 253 例療效分析. 中國中藥雜志, 2003, 28(12): 1203-1206.
111.	Ho JC, Ooi GC, Mok TY, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med, 2003, 168(12): 1449-1456.
112.	王萍, 李明毅, 史玉亮, 等. 不同嚴重急性呼吸綜合征療法的療效評價. 山西醫藥雜志, 2005, 34(4): 270-272.
113.	張燕萍, 苗青, 黃堯洲, 等. 中西醫結合治療 SARS 臨床療效評價研究. 北京: 華北五省市區及廣東省中西醫結合防治 SARS 學術會議, 2003.
114.	李秀惠, 胡建華, 張可, 等. 中西醫結合治療 51 例重癥 SARS 臨床療效觀察. 中華急診醫學雜志, 2004, 13(1): 18-19.
115.	賈衛東. 糖皮質激素在 SARS 治療中應用的回顧性研究. 廣州: 中山大學, 2006.
116.	李秀惠, 張可, 胡建華, 等. 中西醫結合治療 SARS 的臨床療效觀察. 中國中西醫結合雜志, 2003, 23(7): 489-491.
117.	李秀惠, 張可, 胡建華, 等. 中西醫結合治療嚴重急性呼吸綜合征(SARS)臨床療效觀察. 中國醫藥學報, 2003, 18(6): 326-328.
118.	孫中吉, 李玉明, 吉金利, 等. 26 例 SARS 患者的中西醫結合治療效果觀察. 中國中西醫結合急救雜志, 2003, 10(4): 217-219.
119.	李楠, 馬靖, 聶立功, 等. 腎上腺糖皮質激素治療 SARS 的回顧性分析. 北京大學學報(醫學版), 2003, 35(z1): 16-18.
120.	Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA, 2003, 290(24): 3222-3228.
121.	張瑞麟, 焦強, 王保國, 等. 中西醫結合治療 49 例 SARS 臨床對照研究. 中國中西醫結合雜志, 2003, 23(9): 654-657.
122.	白達富, 格勒, 陶布其, 等. 蒙西醫結合治療 SARS 30 例臨床觀察. 中國民族醫藥雜志, 2003, 9(4): 12-12.
123.	劉保延, 何麗云, 梁志偉, 等. 中藥參與對 SARS 治療中腎上腺糖皮質激素用量的影響. 中國中藥雜志, 2005, 30(23): 1874-1877.
124.	仝小林, 李平, 劉鵬, 等. 中西醫結合治療 SARS 237 例療效分析. 北京: 中醫藥防治 SARS 學術研討會, 2003.
125.	李寧, 翟曉輝, 高黎, 等. 中藥乾坤寧治療傳染性非典型肺炎的臨床研究. 中華中西醫雜志, 2003, 4(14): 2090-2093.
126.	Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat middle east respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother, 2015, 70(7): 2129-2132.
127.	Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study. Clin Infect Dis, 2020, 70(9): 1837-1844.
128.	Yang Z, Liu J, Zhou Y, et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect, 2020, 81(1): e13-e20.13-20.
129.	Ye Z, Wang Y, Colunga-Lozano LE, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ, 2020, 192(27): E756-E767.
130.	Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ, 2020, 370: m2980.
131.	Montón C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J, 1999, 14(1): 218-220.
132.	Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 30(3): 269-271.
133.	Eze P, Mezue KN, Nduka CU, et al. Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. Am J Cardiovasc Dis, 2021, 11(1): 93-107.
134.	Diaz-Arocutipa C, Bra?ez-Condorena A, Hernandez AV. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf, 2021, 30(6): 694-706.
135.	Ebina-Shibuya R, Namkoong H, Horita N, et al. Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials. J Thorac Dis, 2021, 13(1): 202-212.
136.	Takla M, Jeevaratnam K. Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. Saudi Pharm J, 2020, 28(12): 1760-1776.
137.	Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med, 2006, 3(9): e343.
138.	Atlanta Centers for Disease Control and Prevention. Severe acute respiratory syndrome (SARS). Available at: https://www.cdc.gov/sars/.
139.	Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med, 2003, 348(20): 1977-1985.
140.	Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl), 2020, 133(9): 1015-1024.
141.	Liu M, Gao Y, Yuan Y, et al. Efficacy and safety of integrated traditional chinese and western medicine for corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. Pharmacol Res, 2020, 158: 104896.
142.	Xiong X, Wang P, Su K, et al. Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis. Pharmacol Res, 2020, 160: 105056.
143.	Sun CY, Sun YL, Li XM. The role of Chinese medicine in COVID-19 pneumonia: A systematic review and meta-analysis. Am J Emerg Med, 2020, 38(10): 2153-2159.
144.	國家衛生健康委辦公廳. 新型冠狀病毒感染的肺炎診療方案(試行第四版). Available at: http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b43209b31739bd0785e67/files/7a9309111267475a99d4306962c8bf78.pdf.
145.	Luo H, Tang QL, Shang YX, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med, 2020, 26(4): 243-250.
146.	Huang CF, Lin SS, Liao PH, et al. The immunopharmaceutical effects and mechanisms of herb medicine. Cell Mol Immunol, 2008, 5(1): 23-31.
147.	Du CY, Zheng KY, Bi CW, et al. Yu Ping Feng San, an ancient Chinese herbal decoction, induces gene expression of anti-viral proteins and inhibits neuraminidase activity. Phytother Res, 2015, 29(5): 656-661.
148.	史洋, 王小平, 白吉慶, 等. 連翹抗菌,抗病毒的藥理作用研究. 中國現代中藥, 2013, 15(11): 950-953.

1. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol, 2020, 92(4): 441-447.
2. Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses - a statement of the coronavirus study group. BioRxiv, 2020: 2020-2022.
3. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Available at: https://www.who.int/publications/m/item/summary-of-probable-sars-cases-with-onset-of-illness-from-1-november-2002-to-31-july-2003.
4. International Committee on Taxonomy of Viruses. ICTV master species list 2018b. v2. Available at: https://talk.ictvonline.org/files/master-species-lists/m/msl/8266.
5. Zhu Y, Li C, Chen L, et al. A novel human coronavirus OC43 genotype detected in mainland China. Emerg Microbes Infect, 2018, 7(1): 173.
6. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
7. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. American: National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/.
8. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis, 2020: ciaa478.
9. Alhazzani W, M?ller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med, 2020, 48(6): e440-e469.
10. Rochwerg B, Agarwal A, Zeng L, et al. Remdesivir for severe covid-19: a clinical practice guideline. BMJ, 2020, 370: m2924.
11. 劉素彥, 王連嵋, 趙雍, 等. 《新型冠狀病毒肺炎診療方案》推薦的中藥注射劑治療呼吸系統感染性疾病的研究進展. 中國實驗方劑學雜志, 2020, 26(12): 1-13.
12. Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg, 2011, 39(2): 91-92.
13. 國家衛生健康委員會, 國家中醫藥管理局. 新型冠狀病毒肺炎診療方案(試行第八版). 中國病毒病雜志, 2020, 10: 321-328.
14. World Health Organization. Clinical management of COVID-19. Living guidance. Available at: https://www.who.int/publications/i/item/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
15. Higgins JP, Altman DG, G?tzsche PC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 2011, 343: d5928.
16. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 2016, 355: i4919.
17. Agresti A. On logit confidence intervals for the odds ratio with small samples. Biometrics, 1999, 55(2): 597-602.
18. Anscombe FJ. On estimating binomial response relations. Biometrika, 1956, 43(3-4): 461-464.
19. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med, 2020, 383(19): 1813-1826.
20. Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol, 2020, 146(1): 137-146.
21. Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother, 2020, 64(9): e01061-1020.
22. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med, 2020, 383(19): 1827-1837.
23. Horby P, Lim WS, Emberson J, et al. Effect of dexamethasone in hospitalized patients with COVID-19 - preliminary report. MedRxiv, 2020: 2020-2026.
24. Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine, 2021, 85: 153242.
25. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA, 2020, 324(5): 460-470.
26. 傅曉霞, 林路平, 譚行華. 中西醫結合治療新型冠狀病毒肺炎 37 例臨床研究. 中藥新藥與臨床藥理, 2020, 31(5): 600-604.
27. 李亞冬, 張文靜. 新冠肺炎中西醫治療方案臨床效果評價. 光明中醫, 2020, 35(9): 1273-1275.
28. 余平, 李葉子, 萬少兵, 等. 連花清瘟顆粒聯合阿比多爾治療輕度新型冠狀病毒肺炎的療效觀察. 中國藥學雜志, 2020, 55(12): 1042-1045.
29. 張傳濤, 楊洋, 由鳳鳴, 等. 從“疫毒夾濕”論治新型冠狀病毒肺炎(COVID-19)的臨床研究. 中藥藥理與臨床, 2020, 36(2): 43-46.
30. 張又莉, 雷亮, 徐勇, 等. 金銀花口服液治療新型冠狀病毒肺炎80例臨床療效分析. 中國藥業, 2020, 29(9): 23-26.
31. 鄭子洲, 白志剛, 李常杰, 等. 中醫辨證治療新型冠狀病毒肺炎效果觀察. 交通醫學, 2020, 34(2): 117-118.
32. 周外民, 趙富明, 李榜龍, 等. 甘草酸二胺在普通型新型冠狀病毒肺炎患者治療中的臨床價值. 病毒學報, 2020, 36(2): 160-164.
33. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med, 2020, 382(19): 1787-1799.
34. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020, 395(10236): 1569-1578.
35. Li Y, Xie Z, Lin W, et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Med (NY), 2020, 1(1): 105-113.
36. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet, 2020, 395(10238): 1695-1704.
37. Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. MedRxiv, 2020: 2020-2023.
38. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ, 2020, 369: m1849.
39. 陳軍, 劉丹萍, 劉莉, 等. 硫酸羥氯喹治療 2019 冠狀病毒病(COVID-19)普通型患者的初步研究. 浙江大學學報(醫學版), 2020, 49: 215-219.
40. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open, 2020, 3(4): e208857.
41. Zhong M, Sun A, Xiao T, et al. A randomized, single-blind, group sequential, active-controlled study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19). MedRxiv, 2020: 2020-2024.
42. Zheng F, Zhou Y, Zhou Z, et al. A novel protein drug, novaferon, as the potential antiviral drug for COVID-19. MedRxiv, 2020: 2020-2024.
43. Lou Y, Liu L, Yao H, et al. Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. Eur J Pharm Sci, 2021, 157: 105631.
44. Zhang Z, Wang S, Tu X, et al. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19. J Med Virol, 2020, 92(11): 2631-2636.
45. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA, 2020, 323(24): 2493-2502.
46. Panagopoulos P, Petrakis V, Panopoulou M, et al. Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection. J Chemother, 2021, 33(3): 193-197.
47. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020, 5(9): 1036-1041.
48. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. MedRxiv, 2020: 2020-2024.
49. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol, 2020, 2(6): e325-e331.
50. Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med, 2020, 76: 43-49.
51. Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med, 2020, 76: 31-35.
52. Mallat J, Hamed F, Balkis M, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease. Medicine (Baltimore), 2020, 99(52): e23720.
53. Lian N, Xie H, Lin S, et al. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect, 2020, 26(7): 917-921.
54. Huang M, Li M, Xiao F, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. MedRxiv, 2020: 2020-2024.
55. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med, 2020, 382(25): 2411-2418.
56. Yuan M, Xu X, Xia D, et al. Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis. Shock, 2020, 54(5): 638-643.
57. 程德忠, 王文菊, 李毅, 等. 51 例新型冠狀病毒肺炎患者應用中藥連花清瘟療效分析: 多中心回顧性研究. 天津中醫藥, 2020, 37: 509-516.
58. 李曠宇, 安薇, 夏飛, 等. 清肺排毒湯加減方聯合抗病毒藥物治療新型冠狀病毒肺炎的回顧性研究. 中草藥, 2020, 51: 2046-2049.
59. 李威, 柳德兵. 甲潑尼龍琥珀酸鈉治療新型冠狀病毒肺炎的有效窗口期. 武漢大學學報(醫學版), 2020, 41(6): 870-874.
60. 李新剛, 徐艷利, 王琳, 等. 糖皮質激素在新型冠狀病毒肺炎重型患者治療中的臨床研究. 首都醫科大學學報, 2020, 41(3): 345-349.
61. 柳麗麗, 馮毅, 孫東, 等. 阿比多爾聯合連花清瘟膠囊治療新型冠狀病毒肺炎的臨床觀察. 廣東醫學, 2020, 41(12): 1207-1210.
62. 秦婭藍, 宋玉燕, 周璐, 等. 熱毒寧聯合甲潑尼龍治療重癥新型冠狀病毒肺炎臨床療效評價. 中國藥業, 2020, 29(9): 19-22.
63. 時佳, 楊宗國, 葉晨, 等. 中西醫結合治上海地區 49 例非危重型新型冠狀病毒肺炎臨床療效觀察. 上海中醫藥雜志, 2020, 54(4): 30-35.
64. 魏茹楠, 蔣賢高, 馬春蓮, 等. 浙江省新型冠狀病毒肺炎患者早期阿比多爾+洛匹那韋/利托那韋+重組干擾素 α-2b 聯合抗病毒治療的多中心、前瞻性研究. 中華臨床感染病雜志, 2020, 13(1): 9-15.
65. 溫春燕, 謝志偉, 李粵平, 等. 洛匹那韋/利托那韋及阿比多爾治療新型冠狀病毒肺炎的療效和安全性觀察. 中華內科雜志, 2020, 59(8): 605-609.
66. Xu P, Huang J, Fan Z, et al. Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study. Microbes Infect, 2020, 22(4-5): 200-205.
67. 楊倩, 孫勤國, 江波, 等. 中西醫結合治療新型冠狀病毒肺炎重癥患者的回顧性臨床研究. 中草藥, 2020, 51(8): 2050-2054.
68. 楊勇, 吳慕禹, 苗麗霞, 等. 高壓氧輔助治療新型冠狀病毒肺炎的介入時機及其臨床療效. 中國醫學物理學雜志, 2020, 37(5): 641-643.
69. 余愛榮, 范星, 趙燕, 等. 洛匹那韋/利托那韋聯合其他抗病毒藥治療新型冠狀病毒肺炎的療效與安全性. 醫藥導報, 2020, 39: 628-632.
70. Carlucci PM, Ahuja T, Petrilli C, et al. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. MedRxiv, 2020: 2020-2025.
71. Quartuccio L, Sonaglia A, McGonagle D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care. J Clin Virol, 2020, 129: 104444.
72. Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust, 2020, 212(9): 416-420.
73. Yu B, Li C, Chen P, et al. Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. MedRxiv, 2020: 2020-2024.
74. Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Infect, 2020, 81(1): e1-e5.
75. 薛平, 柳湘潔, 雷超, 等. 老年普通型新型冠狀病毒肺炎治療中短期小劑量糖皮質激素應用觀察. 山東醫藥, 2020, 60(15): 1-5.
76. Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for treatment of severe covid-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms, 2020, 8(5): 695.
77. Lan X, Shao C, Zeng X, et al. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study. Int J Clin Pharmacol Ther, 2021, 59(5): 378-385.
78. 夏文廣, 安長青, 鄭嬋娟, 等. 中西醫結合治療新型冠狀病毒肺炎 34 例臨床研究. 中醫雜志, 2020, 61: 375-382.
79. 瞿香坤, 郝樹立, 馬景賀, 等. 疏風解毒膠囊聯合阿比多爾治療新型冠狀病毒肺炎的回顧性研究. 中草藥, 2020, 51(5): 1167-1170.
80. 陳軍, 凌云, 席秀紅, 等. 洛匹那韋利托那韋和阿比多爾用于治療新型冠狀病毒肺炎的有效性研究. 中華傳染病雜志, 2020, 38: 86-89.
81. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing), 2020, 6(10): 1192-1198.
82. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 2020, 56(1): 105949.
83. 劉凡. 中西醫結合治療新型冠狀病毒肺炎 42 例療效觀察. 中國管理科學研究院商學院管理創新成果匯編(一). 北京: 中國管理科學研究院商學院, 2020: 7.
84. Fadel R, Morrison AR, Vahia A, et al. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis, 2020, 71(16): 2114-2120.
85. 肖琦, 蔣茵婕, 吳思思, 等. 中藥疏風解毒膠囊聯合阿比多爾治療輕癥新型冠狀病毒肺炎的價值分析. 中國中醫急癥, 2020, 29: 756-758.
86. 王融冰, 劉軍民, 江宇泳, 等. 中西醫結合治療 SARS 療效初步分析. 中國中西醫結合雜志, 2003, 23(7): 492-493.
87. Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol, 2003, 52(Pt 8): 715-720.
88. 張立山, 武維屏, 侯一軍, 等. 中西醫結合治療傳染性非典型肺炎 30 例臨床觀察. 中醫雜志, 2004, 45(9): 675-677.
89. 張允嶺, 張曉梅, 金耀文, 等. 中西醫結合治療 65 例非典型肺炎(SARS)的臨床研究. 北京中醫藥大學學報, 2003, 26(6): 60-64.
90. 趙春惠, 李秀惠, 張可, 等. 77 例 SARS 患者中西醫結合治療隨機對照研究. 中國中西醫結合急救雜志, 2003, 10(4): 197-200.
91. 黃小波, 李宗信, 李斌, 等. 中西醫結合治療 SARS 的臨床療效觀察. 中國中醫藥信息雜志, 2004, 11(2): 144-145.
92. 李志軍, 李慶, 鮑鳳和, 等. 中西醫結合治療 SARS 臨床研究. 杭州: 全國 SARS 防治學術交流會, 2003.
93. 王融冰, 劉軍民, 吳云忠, 等. 中西醫結合治療 SARS 療效分析. 北京: 中醫藥防治 SARS 學術研討會, 2003.
94. 張漢豐, 馬國強, 郝富, 等. 蒙藥清熱八味散(額日赫木-8)對 SARS 的臨床研究. 內蒙古醫學雜志, 2004, 36(10): 732-734.
95. 李海, 盧誠震, 唐克誠, 等. 柴胡滴丸聯合藿香正氣滴丸治療 SARS 的臨床觀察. 中國中西醫結合雜志, 2004, 24(4): 321-324.
96. 任愛民, 張淑文, 王寶恩, 等. 中西醫結合治療 SARS 的臨床研究. 杭州: 全國 SARS 防治學術交流會, 2003.
97. 李宗信, 黃小波, 李斌, 等. 中西醫結合治療傳染性非典型肺炎 122 例臨床研究. 中醫雜志, 2004, 45(7): 510-511.
98. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol, 2004, 31(4): 304-309.
99. 王融冰, 劉軍民, 江宇泳, 等. 中醫藥為主治療 SARS11 例. 北京中醫, 2003, 22(3): 8-9.
100. 張紓難. 中西醫結合治療 SARS 所致肺纖維化療效總結及其臨床特點的分析. 中國全科醫學, 2003, 6(7): 576-577.
101. 黃小波, 李宗信, 李斌, 等. 中西醫結合治療老年 SARS 患者的臨床研究. 中國老年學雜志, 2004, 24(3): 223-225.
102. Li S, Wang R, Zhang Y, et al. Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS. Am J Chin Med, 2006, 34(6): 937-947.
103. 張曉梅, 張允嶺, 楊祖福, 等. 非典 1, 2, 3 號系列方藥治療 SARS 的臨床療效觀察. 中國醫藥學報, 2003, 18(6): 323-325.
104. 夏祖昌, 張重剛, 徐立然, 等. 中西醫結合治療 SARS 證治規律的臨床研究. 中華中醫藥雜志, 2005, 20(4): 243-244.
105. 康靜, 陳恒雯, 劉仲云. 中西醫結合治療傳染性非典型肺炎 43 例臨床觀察. 山西中醫, 2003, 19(4): 34-35.
106. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect, 2004, 10(7): 676-678.
107. Muller MP, Dresser L, Raboud J, et al. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy, 2007, 27(4): 494-503.
108. 李平, 劉保延, 翁維良, 等. 中西醫結合治療對 SARS 肺部炎癥的影響研究. 北京中醫藥大學學報, 2005, 28(4): 55-57.
109. Leong HN, Ang B, Earnest A, et al. Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003. Trop Med Int Health, 2004, 9(8): 923-927.
110. 付琦, 李志剛, 賈寶輝, 等. 中西藥聯合治療 SARS 253 例療效分析. 中國中藥雜志, 2003, 28(12): 1203-1206.
111. Ho JC, Ooi GC, Mok TY, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med, 2003, 168(12): 1449-1456.
112. 王萍, 李明毅, 史玉亮, 等. 不同嚴重急性呼吸綜合征療法的療效評價. 山西醫藥雜志, 2005, 34(4): 270-272.
113. 張燕萍, 苗青, 黃堯洲, 等. 中西醫結合治療 SARS 臨床療效評價研究. 北京: 華北五省市區及廣東省中西醫結合防治 SARS 學術會議, 2003.
114. 李秀惠, 胡建華, 張可, 等. 中西醫結合治療 51 例重癥 SARS 臨床療效觀察. 中華急診醫學雜志, 2004, 13(1): 18-19.
115. 賈衛東. 糖皮質激素在 SARS 治療中應用的回顧性研究. 廣州: 中山大學, 2006.
116. 李秀惠, 張可, 胡建華, 等. 中西醫結合治療 SARS 的臨床療效觀察. 中國中西醫結合雜志, 2003, 23(7): 489-491.
117. 李秀惠, 張可, 胡建華, 等. 中西醫結合治療嚴重急性呼吸綜合征(SARS)臨床療效觀察. 中國醫藥學報, 2003, 18(6): 326-328.
118. 孫中吉, 李玉明, 吉金利, 等. 26 例 SARS 患者的中西醫結合治療效果觀察. 中國中西醫結合急救雜志, 2003, 10(4): 217-219.
119. 李楠, 馬靖, 聶立功, 等. 腎上腺糖皮質激素治療 SARS 的回顧性分析. 北京大學學報(醫學版), 2003, 35(z1): 16-18.
120. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA, 2003, 290(24): 3222-3228.
121. 張瑞麟, 焦強, 王保國, 等. 中西醫結合治療 49 例 SARS 臨床對照研究. 中國中西醫結合雜志, 2003, 23(9): 654-657.
122. 白達富, 格勒, 陶布其, 等. 蒙西醫結合治療 SARS 30 例臨床觀察. 中國民族醫藥雜志, 2003, 9(4): 12-12.
123. 劉保延, 何麗云, 梁志偉, 等. 中藥參與對 SARS 治療中腎上腺糖皮質激素用量的影響. 中國中藥雜志, 2005, 30(23): 1874-1877.
124. 仝小林, 李平, 劉鵬, 等. 中西醫結合治療 SARS 237 例療效分析. 北京: 中醫藥防治 SARS 學術研討會, 2003.
125. 李寧, 翟曉輝, 高黎, 等. 中藥乾坤寧治療傳染性非典型肺炎的臨床研究. 中華中西醫雜志, 2003, 4(14): 2090-2093.
126. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat middle east respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother, 2015, 70(7): 2129-2132.
127. Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study. Clin Infect Dis, 2020, 70(9): 1837-1844.
128. Yang Z, Liu J, Zhou Y, et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect, 2020, 81(1): e13-e20.13-20.
129. Ye Z, Wang Y, Colunga-Lozano LE, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ, 2020, 192(27): E756-E767.
130. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ, 2020, 370: m2980.
131. Montón C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J, 1999, 14(1): 218-220.
132. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 30(3): 269-271.
133. Eze P, Mezue KN, Nduka CU, et al. Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. Am J Cardiovasc Dis, 2021, 11(1): 93-107.
134. Diaz-Arocutipa C, Bra?ez-Condorena A, Hernandez AV. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf, 2021, 30(6): 694-706.
135. Ebina-Shibuya R, Namkoong H, Horita N, et al. Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials. J Thorac Dis, 2021, 13(1): 202-212.
136. Takla M, Jeevaratnam K. Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. Saudi Pharm J, 2020, 28(12): 1760-1776.
137. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med, 2006, 3(9): e343.
138. Atlanta Centers for Disease Control and Prevention. Severe acute respiratory syndrome (SARS). Available at: https://www.cdc.gov/sars/.
139. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med, 2003, 348(20): 1977-1985.
140. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl), 2020, 133(9): 1015-1024.
141. Liu M, Gao Y, Yuan Y, et al. Efficacy and safety of integrated traditional chinese and western medicine for corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. Pharmacol Res, 2020, 158: 104896.
142. Xiong X, Wang P, Su K, et al. Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis. Pharmacol Res, 2020, 160: 105056.
143. Sun CY, Sun YL, Li XM. The role of Chinese medicine in COVID-19 pneumonia: A systematic review and meta-analysis. Am J Emerg Med, 2020, 38(10): 2153-2159.
144. 國家衛生健康委辦公廳. 新型冠狀病毒感染的肺炎診療方案(試行第四版). Available at: http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b43209b31739bd0785e67/files/7a9309111267475a99d4306962c8bf78.pdf.
145. Luo H, Tang QL, Shang YX, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med, 2020, 26(4): 243-250.
146. Huang CF, Lin SS, Liao PH, et al. The immunopharmaceutical effects and mechanisms of herb medicine. Cell Mol Immunol, 2008, 5(1): 23-31.
147. Du CY, Zheng KY, Bi CW, et al. Yu Ping Feng San, an ancient Chinese herbal decoction, induces gene expression of anti-viral proteins and inhibits neuraminidase activity. Phytother Res, 2015, 29(5): 656-661.
148. 史洋, 王小平, 白吉慶, 等. 連翹抗菌,抗病毒的藥理作用研究. 中國現代中藥, 2013, 15(11): 950-953.

Chinese Journal of Evidence-Based Medicine

Efficacy of treatments for β-coronaviruses associated respiratory diseases: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content